Kezar Life Sciences Analyst Ratings
Kezar Life Sciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/05/2023 | — | JonesTrading | Downgrades | Buy → Hold | |
| 09/25/2023 | 1984.42% | HC Wainwright & Co. | $18 → $20 | Maintains | Buy |
| 08/11/2023 | — | Wells Fargo | Downgrades | Overweight → Equal-Weight | |
| 08/11/2023 | 1775.98% | HC Wainwright & Co. | $19 → $18 | Maintains | Buy |
| 05/12/2023 | 1880.2% | HC Wainwright & Co. | $21 → $19 | Maintains | Buy |
| 05/12/2023 | 1254.87% | Wells Fargo | $14 → $13 | Maintains | Overweight |
| 03/16/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 03/16/2023 | 2088.64% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 01/03/2023 | 1359.09% | Wells Fargo | $17 → $14 | Maintains | Overweight |
| 08/12/2022 | 2088.64% | HC Wainwright & Co. | $20 → $21 | Maintains | Buy |
| 06/28/2022 | 1671.76% | Wells Fargo | $13 → $17 | Maintains | Overweight |
| 05/13/2022 | 1254.87% | Wells Fargo | $14 → $13 | Maintains | Overweight |
| 05/04/2022 | 1359.09% | Wells Fargo | $19 → $14 | Maintains | Overweight |
| 03/18/2022 | 2192.86% | HC Wainwright & Co. | $20 → $22 | Maintains | Buy |
| 12/08/2021 | 1880.2% | Wells Fargo | → $19 | Initiates Coverage On | → Overweight |
| 11/16/2021 | 1984.42% | HC Wainwright & Co. | $12 → $20 | Maintains | Buy |
| 07/20/2021 | 1359.09% | JonesTrading | → $14 | Initiates Coverage On | → Buy |
| 06/04/2020 | 1150.65% | HC Wainwright & Co. | $9 → $12 | Maintains | Buy |
| 05/05/2020 | 837.99% | HC Wainwright & Co. | $15 → $9 | Reiterates | → Buy |
| 03/13/2020 | 1775.98% | Wells Fargo | $30 → $18 | Maintains | Overweight |
| 07/29/2019 | 1463.31% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 10/05/2023 | - | Jones Trading | 评级下调 | 购买→Hold | |
| 09/25/2023 | 1984.42% | HC Wainwright公司 | $18→$20 | 维护 | 买 |
| 2023年08月11日 | - | 富国银行 | 评级下调 | 超重→等重 | |
| 2023年08月11日 | 1775.98% | HC Wainwright公司 | $19→$18 | 维护 | 买 |
| 2023年05月12日 | 1880.2% | HC Wainwright公司 | $21→$19 | 维护 | 买 |
| 2023年05月12日 | 1254.87% | 富国银行 | $14→$13 | 维护 | 超重 |
| 03/16/2023 | - | 威廉·布莱尔 | 评级下调 | 跑赢→市场表现 | |
| 03/16/2023 | 2088.64% | HC Wainwright公司 | →$21 | 重申 | →购买 |
| 01/03/2023 | 1359.09% | 富国银行 | $17→$14 | 维护 | 超重 |
| 2022年08月12日 | 2088.64% | HC Wainwright公司 | $20→$21 | 维护 | 买 |
| 2022/06/28 | 1671.76% | 富国银行 | $13→$17 | 维护 | 超重 |
| 2022年05月13日 | 1254.87% | 富国银行 | $14→$13 | 维护 | 超重 |
| 05/04/2022 | 1359.09% | 富国银行 | $19→$14 | 维护 | 超重 |
| 03/18/2022 | 2192.86% | HC Wainwright公司 | $20→$22 | 维护 | 买 |
| 12/08/2021 | 1880.2% | 富国银行 | →$19 | 开始承保 | →超重 |
| 2021年11月16日 | 1984.42% | HC Wainwright公司 | $12→$20 | 维护 | 买 |
| 07/20/2021 | 1359.09% | Jones Trading | →$14 | 开始承保 | →购买 |
| 06/04/2020 | 1150.65% | HC Wainwright公司 | $9→$12 | 维护 | 买 |
| 05/05/2020 | 837.99% | HC Wainwright公司 | $15→$9 | 重申 | →购买 |
| 03/13/2020 | 1775.98% | 富国银行 | $30→$18 | 维护 | 超重 |
| 2019年07月29日 | 1463.31% | HC Wainwright公司 | →$15 | 开始承保 | →购买 |
What is the target price for Kezar Life Sciences (KZR)?
Kezar生命科学公司(KZR)的目标价是多少？
The latest price target for Kezar Life Sciences (NASDAQ: KZR) was reported by JonesTrading on October 5, 2023. The analyst firm set a price target for $0.00 expecting KZR to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
琼斯交易公司于2023年10月5日报道了科扎生命科学公司(纳斯达克代码：KZR)的最新目标价。这家分析公司将KZR的目标价设定为0.00美元，预计KZR将在12个月内下跌(可能下跌-100.00%)。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Kezar Life Sciences (KZR)?
Kezar Life Science(KZR)的最新分析师评级是多少？
The latest analyst rating for Kezar Life Sciences (NASDAQ: KZR) was provided by JonesTrading, and Kezar Life Sciences downgraded their hold rating.
凯撒生命科学(纳斯达克代码：KZR)的最新分析师评级由琼斯交易公司提供，凯撒生命科学下调了其持有评级。
When is the next analyst rating going to be posted or updated for Kezar Life Sciences (KZR)?
Kezar Life Science(KZR)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kezar Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kezar Life Sciences was filed on October 5, 2023 so you should expect the next rating to be made available sometime around October 5, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Kezar Life Science的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Kezar生命科学的上一次评级是在2023年10月5日提交的，所以你应该预计下一次评级将在2024年10月5日左右的某个时候提供。
Is the Analyst Rating Kezar Life Sciences (KZR) correct?
分析师对Kezar Life Science(KZR)的评级正确吗？
While ratings are subjective and will change, the latest Kezar Life Sciences (KZR) rating was a downgraded with a price target of $0.00 to $0.00. The current price Kezar Life Sciences (KZR) is trading at is $0.96, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Kezar Life Science(KZR)评级被下调，目标价为0.00美元至0.00美元。Kezar Life Science(KZR)目前的股价为0.96美元，超出了分析师的预测范围。